Rockefeller Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Rockefeller Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Hold	63,000	–	–	﹤0.01%	2372
2026 Q1	$284K	Hold	63,000	–	–	﹤0.01%	2288
2025 Q4	$303K	Hold	63,000	–	–	﹤0.01%	2154
2025 Q3	$286K	Buy	+63,000	New	+$231K	﹤0.01%	2044
2025 Q2	–	Sell	-63,000	Closed	-$220K	–	1715
2025 Q1	$220K	Sell	63,000 -43,615	-41%	-$145K	﹤0.01%	1643
2024 Q4	$349K	Buy	106,615 +43,615	+69%	+$160K	﹤0.01%	1570
2024 Q3	$243K	Buy	+63,000	New	+$242K	﹤0.01%	1576

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rockefeller Capital Management's ABUS Position: Q2 2026 in Review

Rockefeller Capital Management held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 63,000 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

Rockefeller Capital Management first reported a position in ABUS in Q3 2024 and has held it in 7 quarters since. The position peaked at $349K in Q4 2024. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Rockefeller Capital Management held 63,000 shares of Arbutus Biopharma worth $302K as of Q2 2026.
Rockefeller Capital Management left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2372 holding.
Rockefeller Capital Management first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 7 quarters since.
Rockefeller Capital Management's Arbutus Biopharma position peaked at $349K in Q4 2024.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.